Kwality Pharmaceuticals

Kwality Pharmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Kwality Pharmaceuticals (539997.BO) as of Nov 5, 2026 is 69.56 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 55.23 % — a change of 25.95% (higher).

FCF Conversion

69.56 %

YoY

25.95%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Kwality Pharmaceuticals is 2025 69.56 % . FCF Conversion Rate (FCF/EBITDA) of Kwality Pharmaceuticals was 2024 55.23 % . It decreases by 25.95% higher compared to the previous year.

The Kwality Pharmaceuticals FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-152.37 INR
Jan 1, 2019
23.24 INR
Jan 1, 2020
-175.72 INR
Jan 1, 2021
21.83 INR
Jan 1, 2022
4.54 INR
Jan 1, 2023
-32.48 INR
Jan 1, 2024
55.23 INR
Jan 1, 2025
69.56 INR
The Kwality Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
69.56 %+25.95%
55.23 %-270.05%
-32.48 %-815.74%
4.54 %-79.21%
21.83 %-112.42%
-175.72 %-856.02%
23.24 %-115.25%
-152.37 %+105.44%
-74.17 %-78.78%
-349.58 %+798.72%
-38.90 %-90.98%
-431.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Kwality Pharmaceuticals Stock analysis

What does Kwality Pharmaceuticals do? Kwality Pharmaceuticals Pvt Ltd manufactures pharmaceutical formulations including liquid orals, powders for oral suspension, tablets, capsules, sterile injections, ointments, and oral rehydration solutions. The company produces drugs in categories such as beta lactam, hormones, cytotoxic oncology, and effervescent. It handles customized business as per client requirements and has 48 production sections across its facilities. Kwality exports its products to Europe, Africa, and Asia, with registered products in these regions. The company operates as a manufacturer, buyer, and seller of pharmaceutical intermediates, chemicals, extracts, alkaloids, and medical preparations. It deals in drug intermediates, chemicals, and other pharmaceutical goods alongside toilet requisites and beverages. Kwality's business model focuses on exporting formulations to international markets, particularly targeting regions where its registered products are approved for sale. Kwality Pharmaceuticals serves as a manufacturer and distributor for pharmaceutical products, catering to global markets through its registered product portfolio. The firm's production capabilities include sterile powders for injections, small volume injectables, and external preparations, supporting diverse medical needs across different regions. Kwality Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kwality Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of Kwality Pharmaceuticals is 69.56 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Kwality Pharmaceuticals changed from 55.23 % to 69.56 %, representing a 25.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Kwality Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Kwality Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Kwality Pharmaceuticals

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Kwality Pharmaceuticals